US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye: Calliditas Therapeutics: Progress made in Q4 – focus is on execution going forward

Calliditas is progressing according to plan with the NEFIGARD Phase III study. We provide an update on recent events.  Read more and download the analysis: http://bit.ly/2SmsckD  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye: Calliditas Therapeutics: Well-positioned late-stage orphan play

We are initiating coverage of Calliditas Therapeutics, a late-stage orphan drug company set to start a Phase III with lead project Nefecon for IgA nephropathy. We see a good case in the stock going forward, with strong sales potential and above-average probability of success. Fair value in our Base Case is SEK 70 per share. Read more and download the initial analysis: http://bit.ly/2zv0S8Z Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://

There are no items matching the current filter
There are no more items matching the current filter
Back to top